COGT News and Press, Cogent Biosciences Inc Com From 06/07/23

WALTHAM, Mass. and BOULDER, Colo., June 07, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Jefferies Healthcare Co...

2023-06-07 01:58:04 ET Biotechnology company, Cogent Biosciences ( NASDAQ: COGT ) stock price declines 7% as it prices previously announced underwritten public offering of 12.5M shares at $12.00 per share. Gross proceeds are expected to be ~$150M, upsized from $12...

2023-06-06 17:21:13 ET Gainers: GeneDx Holdings ( WGS ) +6% . Zumiez ( ZUMZ ) +6% . Stitch Fix ( SFIX ) +6% . LianBio ( LIAN ) +5% . Dave & Buster's Entertainment ( PLAY ) +5% . Losers: Couchbase ( BASE ) -17% ...

-  Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable 2 nd -line GIST patients; data immature to estimate progression free survival (PF...

2023-06-02 15:00:55 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...

2023-05-27 07:02:58 ET Summary Cogent Biosciences recently presented updated preclinical findings on the ErbB2 and FGFR2 programs, showcasing a commitment to developing novel therapies for uncharted disease areas. The company launched Part 2 of the APEX trial to evaluate the effec...

WALTHAM, Mass. and BOULDER, Colo., May 23, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held Monday, June 5, 2...

Lead-in data from Phase 3 PEAK trial to be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting Announced initiation of APEX Part 2 expansion trial; on-track to present initial SUMMIT clinical data in 2H 2023 Ended 1Q 2023 with $220.3 million in cash, ...

Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations In vivo characterization shows a novel, selective, reversible FGFR2 inhibitor has potency against molecular brake mutations and potential advantages over covalen...

2023-04-12 17:16:26 ET Gainers: Dragonfly Energy Holdings  ( DFLI ) +5% . C4 Therapeutics ( CCCC ) +5% . Sana Biotechnology ( SANA ) +4% . SunPower Corporation ( SPWR ) +3% . Cogent Biosciences ( COGT ) +3% . Losers: ...